Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Eric Raymond,Laetitia Dahan,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,D. Smith,Aaron I. Vinik,J Chen,Dieter Hörsch,Pascal Hammel,Bertram Wiedenmann,Eric Van Cutsem,Shem Patyna,D. Lu,Carolyn Blanckmeister,R. Chao,Philippe Ruszniewski

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

2011

The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.

Keywords:

Pancreatic neuroendocrine tumor
Gastroenteropancreatic neuroendocrine tumor
Sunitinib malate
Diabetes mellitus
Tyrosine-kinase inhibitor
Neuroendocrine tumors
Pharmacology
Medicine
Sunitinib
Neuroendocrine Cancer
Surgery
Cancer research
Receptor
disease progression

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

1869

Citations